Search research articles
Contact Us
Filters
Showing results (31-40 of 277) with videos related to
Page
of 28
Sort By:
Targeted Oncology
|
February 13, 2013
Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation
Filip Janku, Jennifer J Wheler, David S Hong, et al.
Oncotarget
|
March 28, 2013
A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal
Filip Janku, Helen J Huang, Laura S Angelo, et al.
The Oncologist
|
April 8, 2014
STAT3 inhibitors: finding a home in lymphoma and leukemia
Javier Munoz, Navjot Dhillon, Filip Janku, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 19, 2011
Novel therapeutic targets in non-small cell lung cancer
Filip Janku, Ignacio Garrido-Laguna, Lubos B Petruzelka, et al.
Discovery Medicine
|
June 30, 2016
Targeting isocitrate dehydrogenase (IDH) in cancer
Takeo Fujii, Muhammad Rizwan Khawaja, Courtney D DiNardo, et al.
Cancer
|
June 5, 2015
The mu opioid receptor: A new target for cancer therapy?
Patrick A Singleton, Jonathan Moss, Daniel D Karp, et al.
Oncotarget
|
June 17, 2014
Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing
Filip Janku, Ahmed O Kaseb, Apostolia M Tsimberidou, et al.
Bulletin Du Cancer
|
December 8, 2004
4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study
Filip Janku, Olga Pribylova, Martina Zimovjanova, et al.
Oncoscience
|
September 22, 2023
Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery
Mohamed A Gouda, Filip Janku, Neeta Somaiah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 25, 2010
Response of histiocytoses to imatinib mesylate: fire to ashes
Filip Janku, Hesham M Amin, Dan Yang, et al.
Page
of 28
Search research articles
Search
Showing results (31-40 of 277) with videos related to
Sort By:
Page
of 28
Targeted Oncology
|
February 13, 2013
Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation
Filip Janku, Jennifer J Wheler, David S Hong, et al.
Oncotarget
|
March 28, 2013
A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal
Filip Janku, Helen J Huang, Laura S Angelo, et al.
The Oncologist
|
April 8, 2014
STAT3 inhibitors: finding a home in lymphoma and leukemia
Javier Munoz, Navjot Dhillon, Filip Janku, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 19, 2011
Novel therapeutic targets in non-small cell lung cancer
Filip Janku, Ignacio Garrido-Laguna, Lubos B Petruzelka, et al.
Discovery Medicine
|
June 30, 2016
Targeting isocitrate dehydrogenase (IDH) in cancer
Takeo Fujii, Muhammad Rizwan Khawaja, Courtney D DiNardo, et al.
Cancer
|
June 5, 2015
The mu opioid receptor: A new target for cancer therapy?
Patrick A Singleton, Jonathan Moss, Daniel D Karp, et al.
Oncotarget
|
June 17, 2014
Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing
Filip Janku, Ahmed O Kaseb, Apostolia M Tsimberidou, et al.
Bulletin Du Cancer
|
December 8, 2004
4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study
Filip Janku, Olga Pribylova, Martina Zimovjanova, et al.
Oncoscience
|
September 22, 2023
Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery
Mohamed A Gouda, Filip Janku, Neeta Somaiah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 25, 2010
Response of histiocytoses to imatinib mesylate: fire to ashes
Filip Janku, Hesham M Amin, Dan Yang, et al.
Page
of 28